新型前列环素受体激动剂selexipag

A novel prostacyclin receptor agonist,selexipag

selexipag是一种口服的选择性前列环素受体激动剂,可松弛血管壁平滑肌,扩张血管,降低肺动脉血管的压力。2015年12月本品由美国FDA经标准审评程序获准上市,用于肺动脉高压的治疗。与安慰剂相比,本品可有效降低肺动脉高压的住院率和疾病恶化风险。本文对其作用机制、药动学、药效学、临床试验、用法与用量、药物相互作用、安全性以及特殊人群用药等方面做一综述。

Selexipag belongs to a class of drugs called oral selective prostacyclin receptor agonists. The drug acts by relaxing muscles in the walls of blood vessels to dilate blood vessels and decrease the elevated pressure in the vessels supplying blood to the lungs. In December 2015,selexipag was approved by the standard approval process of the US FDA to treat adults with pulmonary arterial hypertension（ PAH）. Selexipag was shown to be effective in reducing hospitalization rate for PAH and reducing the risk of disease progression compared to placebo.In this article,the mechanism,pharmacokinetics,pharmacodynamics,clinical studies,dosage and administration,drug interactions,safety,and use in special populations of selexipag were reviewed.